Oritavancin Side Effects: What Studies Report

Oritavancin is a long-acting lipoglycopeptide antibiotic, not a research peptide sold for laboratory use. It is a semisynthetic derivative of a glycopeptide scaffold and is administered intravenously in a hospital or infusion-centre setting. Because the compound is an approved human medicine, the published literature on its adverse-event profile is comparatively rich: randomised registrational trials, pooled analyses, real-world cohorts, systematic reviews and pharmacology monographs all describe what was observed. This page summarises that literature. It does not describe how the drug should be used, and it is not a substitute for a prescribing label or a clinician's judgement.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision.

What Was Studied, and How

A 2014 drug monograph in Hospital Pharmacy described oritavancin diphosphate as a lipoglycopeptide given as a single 1200 mg intravenous dose for acute bacterial skin and skin structure infections, and reviewed its pharmacology, spectrum and safety considerations (PMID 25673895). A 2016 review in The Consultant Pharmacist similarly characterised oritavancin as a novel lipoglycopeptide and summarised its pharmacokinetic and tolerability profile for pharmacists (PMID 26842686).

A 2022 paper in Open Forum Infectious Diseases described Kimyrsa, an oritavancin-containing product, reporting a clinical study and a review of the product's properties including a 1200 mg dose delivered over a shorter infusion time in a smaller diluent volume than the earlier formulation (PMID 35392455). Formulation differences matter for the side-effect conversation because several of the most frequently described events in the literature are tied to the infusion itself rather than to systemic drug exposure.

Adverse Events in Registrational Trials: What Studies Report

The SOLO I and SOLO II programme compared oritavancin with vancomycin in adults with acute bacterial skin and skin structure infections. A 2017 analysis in Open Forum Infectious Diseases examined efficacy and safety of a single 1200 mg oritavancin dose relative to intravenous vancomycin among patients managed in the outpatient setting, and researchers reported that clinical response and adverse-event profiles were comparable between the two arms in that population (PMID 28480266). That paper is the most directly relevant randomised safety comparison, because it isolates patients who did not require inpatient care and therefore had fewer competing sources of adverse events.

The categories of treatment-emergent events described across the oritavancin literature are the ones common to intravenous antibacterials generally: gastrointestinal complaints such as nausea and vomiting, headache, infusion-site reactions, and laboratory abnormalities. A 2026 systematic review in Drugs in Context evaluated oritavancin for Gram-positive infections across on-label and off-label indications and collated the safety signals reported by the included studies (PMID 41891114).

Infusion-Related and Hypersensitivity Reactions: What Studies Report

Glycopeptides as a class are associated with infusion-rate-dependent reactions that are distinct from true allergy. A 2020 review in Pharmacy examined glycopeptide hypersensitivity and adverse reactions, distinguishing infusion reactions driven by direct mast-cell activation from IgE-mediated immediate hypersensitivity and from delayed T-cell-mediated syndromes, and the authors reported that these mechanisms have different implications for cross-reactivity within the class (PMID 32326261). That review is the clearest published framework for interpreting flushing, pruritus, rash or chest discomfort occurring during a lipoglycopeptide infusion.

Because infusion reactions are rate-related, formulation and infusion duration are part of the safety discussion. The 2022 Kimyrsa report described a 1200 mg oritavancin product administered over a shortened infusion period and reviewed the tolerability observations associated with that presentation (PMID 35392455).

Laboratory Test Interference: What Studies Report

Oritavancin's pharmacologic monographs describe an effect that is not a clinical toxicity but is clinically important: interference with certain phospholipid-dependent coagulation assays, which can produce spuriously abnormal results for a period after dosing. The 2014 Hospital Pharmacy monograph covered this among the safety and monitoring considerations for the single 1200 mg intravenous dose (PMID 25673895), and the 2016 Consultant Pharmacist review likewise addressed the drug's laboratory and monitoring profile alongside its pharmacokinetics (PMID 26842686).

A separate monitoring question is whether drug concentrations should be measured at all. A 2025 narrative review in Clinical Microbiology and Infection updated clinicians on therapeutic drug monitoring of antibiotics used for methicillin-resistant Staphylococcus aureus infections, and researchers reported that the evidence base for routine concentration monitoring differs sharply between agents, being well established for some and undeveloped for others (PMID 39209264). For a long-half-life single-dose agent, that distinction shapes how adverse events are detected: there is no routine level to check, so tolerability is assessed clinically.

Real-World and Off-Label Cohorts: What Studies Report

Much of the published tolerability experience with oritavancin now comes from observational use outside the skin-infection indication, where patients are older, sicker and often receiving repeated doses.

A 2019 study in the Journal of Antimicrobial Chemotherapy described on- and off-label utilisation of dalbavancin and oritavancin for Gram-positive infections and characterised the indications for which these long-acting lipoglycopeptides were being used together with the outcomes and adverse events recorded (PMID 31322694). A 2024 report in JAC-Antimicrobial Resistance described a tertiary hospital's experience with expanded use of oritavancin, and the authors reported indications, tolerability and outcomes for that cohort (PMID 39493938).

Bloodstream infection is the off-label setting most often examined. A 2024 paper in BMC Infectious Diseases evaluated oritavancin as sequential therapy for Gram-positive bloodstream infections, describing how the agent was used after initial therapy and what outcomes followed (PMID 38267844). A 2025 retrospective single-arm cohort in Open Forum Infectious Diseases examined oritavancin for Staphylococcus aureus bacteraemia and the study reported clinical outcomes and safety observations in that population (PMID 40657166). Single-arm retrospective designs cannot separate drug-attributable events from the natural course of bacteraemia, which is a limitation the authors of such cohorts acknowledge.

Where the Evidence Sits: A Comparison

Service-Level Considerations Described in the Literature

Adverse events are not the only variable that determines whether a long-acting agent is used. A 2025 analysis in Federal Practitioner asked whether oritavancin and dalbavancin were more cost effective than conventional outpatient parenteral antimicrobial therapy at a Veterans Affairs medical centre, and researchers reported on the economic comparison between single-dose lipoglycopeptides and multi-day catheter-based regimens (PMID 40832670). Line-associated complications avoided by single-dose therapy are part of that comparison, which is why safety and service-delivery questions are frequently discussed together in the oritavancin literature.

What the Published Literature Does Not Establish

• Long-term or repeated-dosing safety. The randomised evidence summarised in the SOLO outpatient analysis concerned a single 1200 mg dose (PMID 28480266); repeat-dose experience is largely observational, as described in the expanded-use cohort (PMID 39493938).
• Comparative adverse-event rates in bacteraemia. The 2025 bacteraemia study was a single-arm retrospective cohort without a randomised comparator (PMID 40657166).
• A concentration threshold linked to toxicity. The 2025 therapeutic drug monitoring review described how unevenly monitoring evidence is distributed across anti-MRSA antibiotics (PMID 39209264).
• Any use outside clinical medicine. Oritavancin is an intravenous prescription antibacterial; the published record contains no support for non-clinical or self-directed use, and the systematic review of on- and off-label use framed every application within hospital or infusion-service care (PMID 41891114).

How to Read This Evidence

Three cautions apply when interpreting any adverse-event summary of this kind. First, randomised trial populations are selected and generally healthier than the patients described in later real-world series such as the 2019 utilisation study (PMID 31322694). Second, observational cohorts record events without a comparator, so background illness and drug effect cannot be separated, a limitation visible in the sequential-therapy bloodstream infection report (PMID 38267844). Third, class-level reviews describe mechanisms rather than incidence rates, as in the 2020 glycopeptide hypersensitivity review (PMID 32326261).

Readers who want the underlying pharmacology — mechanism, half-life, spectrum and why a single dose was developed — will find that material covered separately in the PeptideU oritavancin course at /learn/oritavancin/, which teaches the compound rather than cataloguing its adverse-event literature. This page deliberately stays on the safety record.

Nothing here describes a protocol, schedule or personal course of action. Decisions about antibacterial therapy belong to a licensed prescriber working from the approved product label and the individual clinical picture.

References

• Oritavancin diphosphate (Hospital Pharmacy, 2014)
• Oritavancin: A Novel Lipoglycopeptide (The Consultant Pharmacist, 2016)
• Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials (Open Forum Infectious Diseases, 2017)
• On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections (Journal of Antimicrobial Chemotherapy, 2019)
• Glycopeptide Hypersensitivity and Adverse Reactions (Pharmacy, 2020)
• Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties (Open Forum Infectious Diseases, 2022)
• Oritavancin as sequential therapy for Gram-positive bloodstream infections (BMC Infectious Diseases, 2024)
• Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes (JAC-Antimicrobial Resistance, 2024)
• Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians (Clinical Microbiology and Infection, 2025)
• Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study (Open Forum Infectious Diseases, 2025)
• Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center? (Federal Practitioner, 2025)
• Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use (Drugs in Context, 2026)